Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
SIGA · NASDAQ · Pharmaceutical Preparations
Siga Technologies (SIGA) · oqro.io/stocks/SIGA · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$2.40−0.25 (−9.43%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
No open-market purchase by an insider of Siga Technologies was filed in the last 90 days. The latest on record was on Dec 9, 2019.
Since 2007, Siga Technologies insiders reported 66 open-market purchases and 66 sales on Forms 4 and 5, with purchases in 8 different years, most recently 2019.
No open-market sale by an insider of Siga Technologies (SIGA) was filed with the SEC in the last 90 days.
No trade in Siga Technologies (SIGA) was disclosed by a member of Congress in the last 12 months.
Siga Technologies's next results are expected on Mar 8, 2027. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−58.4% (−$3.37) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $5.77 on Nov 20, 2025 to $2.40 on Nov 20, 2026 (−58.4%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in New York, Ny.
Last 12 months
−58.4%
Market value
$205M
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 3.57M shares sold short (4.2% of shares outstanding), +0.1% vs the previous count, 7.8 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Revenue, fiscal 2025
$94.6M
−31.8% vs the year before
Net income, fiscal 2025
$23.3M
As reported in the annual filing
Shares outstanding
71.9M
As of Oct 26, 2026
In fiscal 2025 the company spent $43.1M on dividends. Cash actually paid, from its cash-flow statement.
Nothing reported yet
New filings show up here as soon as they are processed.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Insiders of Siga Technologies reported 66 open-market purchases and 66 sales since 2007; purchases in 8 different years, most recently 2019.
| Year | Bought | Sold |
|---|---|---|
| 2021 | — | $235K1×1 trade |
| 2020 | — | $213K1×1 trade |
| 2019 | $337K7×7 trades | $452K4×4 trades |
| 2018 | $156K3×3 trades | $258K2×2 trades |
| 2015 | — | $204K14×14 trades |
| 2014 | $573K5×5 trades | $102K3×3 trades |
| 2013 | $109K4×4 trades | $111K3×3 trades |
| 2011 | $584K13×13 trades | $6M10×10 trades |
| 2010 | — | $972K4×4 trades |
| 2009 | $54.8M27×27 trades | $61.2M22×22 trades |
| 2008 | $166K6×6 trades | — |
| 2007 | $1.05M1×1 trade | $42K2×2 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the public record for Siga Technologies over the 12 months to Nov 18, 2026: 1 clinical trial.
Revenue
$1.32M
−49.7% vs the same quarter a year earlier
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net debt
—
Debt —, cash $116M, at Sep 30, 2026
Backlog
$25.6M
Work contracted but not yet delivered, as the company reports it
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 9, 2026.
Revenue and earnings history, 17 fiscal yearsEarnings dates and the stock's moves
No Schedule 13D or 13G filing on SIGA over the last three years: no investor has reported crossing 5% of its stock in that time.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Fiscal year Jan 1, 2025 to Dec 31, 2025, from the annual report filed Mar 10, 2026. Read the filing
−34% on the year before ($133M)
+21% on the year before ($5.39M)
−23% on the year before ($116M)
+689% on the year before ($738K)
$13.9M the year before
$8.38M the year before
The company also reports Non-US ($5.82M), which group lines above and are not added again.
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 5,000 words.
SIGA Technologies, Inc. (“SIGA” or the “Company”) is a commercial-stage pharmaceutical company. The Company sells its lead product, TPOXX® (“oral TPOXX®,” also known as "tecovirimat," "Tecovirimat SIGA," or "TEPOXX (tecovirimat)" in certain international markets), to the U.S. Government and international governments (including government affiliated entities). In certain international markets, the Company may sell TPOXX® through a distributor. Additionally, the Company sells the intravenous formulation of TPOXX® ("IV TPOXX®") to the U.S. Government. TPOXX® is an antiviral drug for the treatment of human smallpox disease caused by variola virus. On July 13, 2018, the United States Food & Drug Administration (“FDA”) approved oral TPOXX® for the treatment of smallpox.
Source: SEC EDGAR, Form 10-K filed Mar 10, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
And 3 more headings in the filing.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Things to keep in mind
0 active phase 3 trials and 1 active phase 2 trial led by this company, mostly in smallpox. The ones with the nearest registered primary completion date still ahead:
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
Last results
Nov 9, 2026
Within the 30 days after it, until Dec 9, 2026
Next results, expected
Mar 8, 2027
Purchases after results
Not enough history
From Siga Technologies's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Siga Technologies's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Against the S&P 500 over the year
Since Nov 18, 2025, SIGA is down 59.8% and the index fund is up 4.5%: 64 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much SIGA moves
Beta 0.9 (1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 249 trading days (1 = in step with it).
Latest annual report filed Mar 10, 2026, compared with the one filed Mar 11, 2025. Read the filing
From time to time, we may be involved in a variety of claims, suits, investigations and proceedings arising from the ordinary course of our business, collections claims, breach of contract claims, labor and employment claims, tax and other matters. Although such claims, suits, investigations and proceedings are inherently uncertain and their results cannot be predicted with certainty, we believe that the resolution of such current pending matters, if any, will not have a material adverse effect on our business, consolidated financial position, results of operations or cash flow.
Source: SEC EDGAR, Form 10-K filed Mar 10, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Off-exchange trading: 38.0% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (18.3% on ATS, 19.7% with other brokers), below its 26-week average of 40.1%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: INTELLIGENT CROSS LLC (15.1%), UBS ATS (12.1%), LIQUIDNET H2O ATS (6.6%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.